Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 23103344.
- Also identified by DOI 10.1016/j.ajog.2012.10.876 and PMC identifier 3974101.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The objective of the study was to evaluate perceived weight gain in women using contraception and determine the validity of self-reported weight gain. We analyzed data from new contraceptive method users who self-reported a weight change at 3, 6, and 12 months after enrollment. We examined a subgroup of participants with objective weight measurements at baseline and 12 months to test the validity of self-reported weight gain. Thirty-four percent of participants (1407 of 4133) perceived weight gain. Compared with copper intrauterine device users, implant users (relative risk, 1.29; 95% confidence interval, 1.10-1.51) and depot medroxyprogesterone acetate users (relative risk, 1.37; 95% confidence interval, 1.14-1.64) were more likely to report perceived weight gain. Women who perceived weight gain experienced a mean weight gain of 10.3 pounds. The sensitivity and specificity of perceived weight gain were 74.6% and 84.4%, respectively. In most women, perceived weight gain represents true weight gain. Implant and depot medroxyprogesterone acetate users are more likely to perceive weight gain among contraception users.
Medical subject headings
- Body Weight
- Contraceptive Agents, Female
- Intrauterine Devices
- Medroxyprogesterone Acetate
- Weight Gain